| Trial | Treatments | Patients | Method |
|---|
| NAVIGATOR nateglinide, 2010 | nateglinide 60mg 3 times daily (n=4645) vs. placebo (n=4661) factorial design: patuents were also randomized between nateglinide or placebo
| subjects with impaired glucose tolerance and either CV disease or CV risk factors
| double-blind Factorial plan Sample size: 4645/4661 Primary endpoint: 3 coprimary: diabetes, CV events FU duration: 5 years
|
| Ristic, 2006 | nateglinide plus metformin (n=133) vs. gliclazide plus metformin (n=129) | Patients with inadequate glucose control on maximal doses of metformin | double-blind Parallel groups Sample size: 133/129 Primary endpoint: FU duration: 24 weeks |
| Marre, 2002 | nateglinide 60 mg, 120 mg before three meals (n=-9) vs. placebo (n=-9) | metformin-treated patients with HbA1c between 6.8% and 11% | double-blind Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: |
| Li, 2009 | Nateglinide (n=-9) vs. repaglinide (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| Li, 2007 | nateglinide 90 mg three times daily (n=115) vs. repaglinide 1.0 mg three times daily (n=115) | Chinese patients with type 2 diabetes | Parallel groups Sample size: 115/115 Primary endpoint: FU duration: 12 weeks |
| Horton, 2000 | 120 mg nateglinide before meals (n=179) vs. placebo (n=172) | patients with an HbA1c level between 6.8 and 11.0% during a 4-week placebo run-in | double-blind Parallel groups Sample size: 179/172 Primary endpoint: FU duration: |
| Hanefeld, 1990 | nateglinide at doses of 30 mg, 60 mg, 120 mg, or 180 mg (n=229) vs. placebo (n=60) | | double-blind Parallel groups Sample size: 229/60 Primary endpoint: FU duration: 12 weeks |
| Saloranta, 2002 | nateglinide (30, 60, or 120 mg, with meals). (n=675) vs. placebo (n=0) | patients with type 2 diabetes but only moderately elevated fasting plasma glucose (FPG = 7.0-8.3 mmol/liter) | double-blind Parallel groups Sample size: 675/0 Primary endpoint: FU duration: 24 weeks |
| Mari, 2005 | 30, 60, or 120 mg nateglinide (n=108) vs. placebo (n=0) | mild type 2 diabetic men and women (fasting glucose 7.0-8.3 mmol/l) on diet treatment | double_blind Parallel groups Sample size: 108/0 Primary endpoint: FU duration: 24 weeks |
| Goldberg, 1998 | repaglinide (n=66) vs. placebo (n=33) | type 2 diabetes | double-blind Parallel groups Sample size: 66/33 Primary endpoint: FU duration: |
| Jovanovic, 2000 | repaglinide 1 mg or repaglinide 4 mg (n=286) vs. placebo (n=75) | | double-blind Parallel groups Sample size: 286/75 Primary endpoint: FU duration: 24 weeks |
| Bech, 2003 | repaglinide initiated at 0.5 mg per meal, increased to 1 mg after 4 weeks if fasting plasma glucose exceeded 7.8 mmol/l. (n=253) vs. placebo (n=0) | pharmacotherapy-naive patients with Type 2 diabetes | double-blind Parallel groups Sample size: 253/0 Primary endpoint: FU duration: 16 weeks |
| Moses, 2001 | 0.5 mg repaglinide at mealtimes (increased to 1 mg after 4 weeks depending on blood glucose response) (n=408) vs. placebo (n=0) | patients with type 2 diabetes considered poorly controlled by diet, but without a history of previous antidiabetic medication | double-blind Parallel groups Sample size: 408/0 Primary endpoint: FU duration: 16 weeks |
